Top Markets
Coin of the day
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
Classifica tra le azioni #42528
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage... TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Prezzo delle azioni
$0.00004
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$979.00
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-60.00%
Paese
US
Scambia TetraLogic Pharmaceuticals Corporation (TLOG)

Categoria

Ricavi di TetraLogic Pharmaceuticals Corporation (TLOG)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di TetraLogic Pharmaceuticals Corporation, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per TetraLogic Pharmaceuticals Corporation da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR